Novel Classes of Biologics vs. TNF-Alpha Inhibitors for Crohn’s Disease and Ulcerative Colitis | Physician & Payer Forum | US | 2015

launch Related Market Assessment Reports

• Systemic Lupus Erythematosus – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

  April 2024

  Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal manifestations…

• Crohn’s Disease – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Adult Crohn’s Disease (US)

  Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and…

• Idiopathic Pulmonary Fibrosis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

  Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. Characterized by the thickening and stiffening of tissues in the lungs, it…

• Psoriasis – Geographic Focus: China – Psoriasis – China In-Depth (China)

  April 2024

  Non-TNF biologics (e.g., IL-17 inhibitors) are gaining momentum in China in the treatment of psoriasis, particularly moderate to severe disease. We expect that the growing psoriasis armamentarium…

• Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast

  The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is…